1. Pink Sheet

EMA Calls For Visual Warnings Among Measures To Restrict Valproate Use

 
• By Vibha Sharma

The European Medicines Agency has recommended that EU member states should introduce further restrictions on the use of valproate-containing medicines to avoid the drug's exposure in pregnancy.

Pregnancy
Restrictions Aim To Avoid Exposure To Valproate Medicines In Pregnancy • Source: Shutterstock

The European Medicines Agency's pharmacovigilance committee, PRAC, has recommended further restrictions to avoid exposure of babies in the womb to valproate-containing medicines, which are used to treat epilepsy, bipolar disorder and migraine.

The recommendations, which include a call to introduce a pregnancy prevention program, apply to the use of valproate medicines in

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

EU Shaping Biotech Act To Unleash SME Potential

 
• By Neena Brizmohun

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 
• By Neena Brizmohun

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.